TNXP - Tonix Pharmaceuticals

-

$undefined

N/A

(N/A)

Tonix Pharmaceuticals NasdaqCM:TNXP Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer's disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder. In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2. Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome. The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure. Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey.

Location: 26 Main Street, Chatham, NJ, 07928, United States | Website: https://www.tonixpharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

32.83M

Cash

98.78M

Avg Qtr Burn

-15.23M

Short % of Float

15.17%

Insider Ownership

0.00%

Institutional Own.

4.22%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

PDUFA

Approval decision

TNX-1300 Details
Cocaine overdose / intoxication

Phase 2

Data readout

TNX-1900 Details
Social Anxiety Disorder

Phase 2

Data readout

Phase 2

Data readout

TNX-1900 Details
Psychiatric disorder, Binge eating disorder

Phase 2

Data readout

TNX-1900 Details
Bone disorder, Bone health, Autism spectrum disorders

Phase 2

Data readout

TNX-102 SL Details
Sleeping disorder, Post-traumatic stress disorder

Phase 2

Update

Phase 2

Update

TNX-2900 Details
Prader-Willi syndrome

Phase 2

Initiation

TNX-102 SL Details
Post-traumatic stress disorder

Phase 2

Initiation

TNX-1500 Details
Kidney transplantation, Graft-versus-host disease , Hematopoietic cell transplantation

Phase 2

Initiation

IND

Submission

TNX-102 SL Details
Alcohol dependence

Failed

Discontinued

TNX-102 SL Details
Agitation, Alzheimer's disease

Failed

Discontinued

Failed

Discontinued

TNX-601 Details
Major depressive disorder

Failed

Discontinued